Moving bispecific antibodies targeting CD20 into B-cell non-Hodgkin lymphomas (NHL) will require finding ways to mitigate their risk of cytokine release syndrome (CRS), which can require hospitalization that outpatient infusion centers cannot provide. However, anti-CD20 bispecifics appear relatively mild in terms of CRS compared to CAR-T therapeutics – which could set them up as competitors to the cell therapies at least in more slow-growing NHL.
CAR-T therapies approved for aggressive NHL – such as Novartis AG’s Kymriah (tisagenlecleucel), Gilead Sciences, Inc.’s Yescarta (axicabtagene...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

